BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27
• 29
• 30
• 31

• Press Releases

  Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash

  December 10, 2024

   · 

  8 min read
• Press Releases

  Children’s Hospital of Philadelphia Researchers Find Precision Medicine Treatment Delivers Strong Results for Infantile Fibrosarcoma and Other Solid Tumors

  December 10, 2024

   · 

  5 min read
• Press Releases

  Lilly announces new $15 billion share repurchase program and seventh consecutive 15% dividend increase

  December 10, 2024

   · 

  3 min read
• Press Releases

  Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

  December 10, 2024

   · 

  19 min read
• Press Releases

  Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma

  December 10, 2024

   · 

  15 min read
• Press Releases

  Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

  December 10, 2024

   · 

  18 min read
• Press Releases

  Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 9, 2024

  December 10, 2024

   · 

  2 min read
• Press Releases

  Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

  December 10, 2024

   · 

  6 min read
• Press Releases

  CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

  December 10, 2024

   · 

  28 min read
• Press Releases

  Keros Therapeutics Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

  December 10, 2024

   · 

  14 min read